TM Owner Gilead Sciences
Sunlenca 463.5mg Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Sunlenca 463.5 mg/1.5 mL injection (lenacapavir, given together with Sunlenca oral tablets) is a first-in-class HIV-1 capsid inhibitor used in combination with other antiretroviral medicines to treat HIV-1 infection in heavily treatment-experienced adults whose current regimen is failing because of multidrug resistance, intolerance or safety concerns.
- Treatment begins with oral tablets and a loading subcutaneous injection given by a healthcare provider, after which maintenance doses are given as a single subcutaneous injection into the abdomen every six months, alongside a fully suppressive background antiretroviral regimen; oral lead-in doses can be self-administered but the injections themselves are given only by a healthcare provider in a clinic or hospital setting.
- Sunlenca is not indicated as a stand-alone HIV treatment and must always be combined with other active antiretroviral agents.
- It has no approved indication outside this heavily treatment-experienced population.
Side Effects
- The most common reactions to Sunlenca are nausea and injection-site reactions, occurring in at least 3% of patients, with injection-site effects including swelling, pain, redness, firm nodules and induration that can persist for many months after an injection.
- There is no boxed warning on the current Sunlenca prescribing information.
- Immune reconstitution syndrome can occur soon after starting any antiretroviral therapy, including Sunlenca, causing inflammatory symptoms from previously hidden infections, and should be reported promptly.
- Because lenacapavir remains in the body for up to 12 months after the last injection, drug interaction risk and the potential for the virus to develop resistance can persist long after stopping treatment, especially if a fully suppressive regimen is not continued.
- Report any lasting lump, pain or skin change at an injection site, or symptoms of a new infection or worsening illness, to your healthcare provider.
Precautions & Warnings
- Sunlenca must always be used together with other fully active antiretroviral drugs, never alone, because resistance can develop quickly if the background regimen does not fully suppress the virus.
- Because lenacapavir levels persist in the body for up to 12 months after the final dose, drug interactions can occur for many months after stopping, and a fully suppressive regimen should be maintained during this tail period wherever possible.
- Sunlenca is contraindicated with strong CYP3A inducers, including rifampin and St John's Wort, because they markedly reduce lenacapavir levels and risk treatment failure.
- Injection-site nodules and induration are common and can be long-lasting; sites are rotated and monitored.
- Sunlenca tablets and injection vials are both stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and do not require refrigeration.
- Use in pregnancy should be discussed with a healthcare provider, since data are still limited, and a pregnancy registry monitors outcomes.
Avoid Interactions
- Sunlenca is contraindicated with strong CYP3A inducers such as rifampin, carbamazepine, phenytoin and St John's Wort, since these drastically lower lenacapavir levels and can lead to loss of viral suppression and resistance; moderate CYP3A inducers are also not recommended.
- Certain antiretrovirals, including efavirenz, nevirapine and tipranavir boosted with ritonavir, are not recommended in combination with Sunlenca because they reduce lenacapavir exposure.
- Because lenacapavir is a CYP3A substrate and can also affect other drugs through this pathway, and because its effects can last up to 9 months after the final dose, any new medicine started during or after Sunlenca treatment should be checked for interactions with a pharmacist or the HIV care team.
- Tell your healthcare provider about every prescription, over-the-counter and herbal product you use, including St John's Wort, before starting Sunlenca and for months after the last dose.
References
Frequently Asked Questions
Sunlenca (lenacapavir) treats HIV-1 in adults who have tried many other HIV medicines and whose virus is now resistant to them. It is always combined with other active antiretroviral drugs, never used alone, to fully suppress the virus in this hard-to-treat, heavily treatment-experienced group.
Sunlenca starts with oral tablets and an injection, then maintenance is a single injection under the skin of your abdomen every 6 months, given by a healthcare provider. You also take a background combination of other antiretroviral medicines every day alongside it.
The most common Sunlenca side effects are nausea and injection-site reactions, including swelling, pain, redness and firm lumps that can last many months. Report any new lump, pain or skin change at the injection site, or signs of a new infection, to your HIV care team.
Avoid St John's Wort and rifampin-type medicines with Sunlenca, since these sharply lower lenacapavir levels and can let HIV become resistant. Tell your HIV team about every other medicine you take, since lenacapavir stays in your body and can interact with new medicines for up to a year.
At each Sunlenca visit, a healthcare provider injects lenacapavir under the skin of your abdomen, then checks the injection site. You may develop a firm lump or swelling there that can last months; this is expected. Your next injection is due 6 months later.
Data on Sunlenca in pregnancy are still limited, so tell your HIV care team if you are or could become pregnant; a pregnancy registry tracks outcomes. Treatment decisions in pregnancy are made individually, balancing HIV control against the limited safety data available.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
